اندازه¬گيري ميزان بيان ژن MMP-9 برای ارزیابی بهبودی بیماران مبتلا به سرطان پستان

Crowe DL, Tsang KJ, Shemirani B. Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia 2001;3(1):27-32.

Martinella-Catusse C, Polette M, Noel A, Gilles C, Dehan P, Munaut C, et al. Down-regulation of MT1-MMP expression by the alpha 3 chain of type IV collagen inhibits bronchial tumor cell line invasion. Lab Invest 2001;81(2):167-75.

Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001;13(2):117-23.

Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I, et al. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001;61(1):376-82.

Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61(1):237-42.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-74.

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92(8):827-839.

Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994;269(9):6632-6636.

Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990;9(4):289-303.

Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53(1):140-6.

Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 2005;236(1):125-32.

Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005;116(3):422-7.

Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 2000;20(2B):1307-10.

Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996;24(5):1058-62.

Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17(3C):2253-8.

Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 1997;84(1):133-6.

Sadeghi M, Motovali-Bashi M, Hojati Z. MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. IJIB 2009;6(1): 33-37.

Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M, et al. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 2000;89(4):389-94.

Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffé ED, et al. Circulating 92-Kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck. Cancer Res 2002;36:127-122.

Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001;34(5):347-52.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52.

Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D'Amico DF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 1999;19(5C):4485-90.

Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues:Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212-27.

La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90(7):1414-21.

Mannello F, Tonti GA. Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007;121(1):216-218.

Ferno M. Prognostic factors in breast cancer: A brief review. Anticancer Res 1998;18(3C):2167-71.

Souhami RL, Tannock I, Hohenberger P, Horiot JC. Oxford textbook of oncology. 2nd ed. New York: Oxford University Press; 2002.p.1725-34.

Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124(7):966-78.

Hashimoto N, Kobayashi M, Tsuji T. Serum Type IV collagen-degrading enzyme in hepatocellular carcinoma with metastasis. Acta Med Okayama 1998;42(1):1-6.

Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Mellon JK. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 2001;7(11):3450-6.